The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of ...

LONDON, UK & SAN FRANCISCO, CA, USA I January 09, 2025 I Verdiva Bio Limited (“Verdiva” or “the Company”) today announced its launch as a clinical-stage ...

PARIS, France I January 9, 2025 I Results from the investigational, randomized, open-label IRAKLIA phase 3 study demonstrated that Sarclisa administered at a ...

Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily. SAN DIEGO, CA, USA I January 8, 2025 I Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), ...

PALO ALTO, CA and NEEDHAM, MA, USA and MELBOURNE, Australia I January 08, 2025 I Bitterroot Bio, a leader in developing innovative medicines in the field of ...

NEW YORK, NY, USA I January 07, 2025 I Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...

CRANFORD, NJ, USA I January 7, 2025 I Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, ...

SEATTLE, WA, USA I January 7, 2025 I Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo ...

The Company has aligned on clinical plan based on a positive FDA meeting, leveraging clinical data from a first-in-human Phase 1 trial published today in ...

New investor Jeito Capital, a global leading private equity fund, led the Series B financing round which also included existing institutional investors EQT, Fountain Healthcare Partners, and Lumira ...

Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 ...

BEIJING, China & ALAMEDA, CA, China & TAIPEI, Taiwan I January 07, 2025 I Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a ...